SK bioscience Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Public, Subsidiary
- Established
- 2018-07-02
- Employees
- 1K
- Market Cap
- -
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
- Conditions
- Japanese Encephalitis Virus Disease
- Interventions
- Biological: GBP560-ABiological: GBP560-BBiological: Normal Saline (Placebo)
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- SK Bioscience Co., Ltd.
- Target Recruit Count
- 402
- Registration Number
- NCT06680128
- Locations
- 🇦🇺
Nucleus Network - Brisbane (Q Pharm), Brisbane, Australia
🇦🇺Nucleus Network - Melbourne, Melbourne, Australia
🇳🇿New Zealand Clinical Research, Christchurch, Central City, New Zealand
A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.
- Conditions
- COVID-19
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- SK Bioscience Co., Ltd.
- Registration Number
- NCT05710289
Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and Older
- Conditions
- COVID-19
- Interventions
- Other: Placebo (Normal Saline)Biological: GBP510 adjuvanted with AS03
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- SK Bioscience Co., Ltd.
- Target Recruit Count
- 840
- Registration Number
- NCT05501522
- Locations
- 🇨🇴
CAIMED (Centro de Atención e Investigación Médica), Chía, Cundinamarca, Colombia
🇨🇴Policlínico Social Del Norte, Bogotá, Colombia
🇳🇵Dhulikhel, Kathmandu, Dhulikhel, Nepal
Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)
- Conditions
- Covid19
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- SK Bioscience Co., Ltd.
- Target Recruit Count
- 4036
- Registration Number
- NCT05007951
- Locations
- 🇰🇷
Korea University Ansan Hostpital, Ansan, Gyeonggi, Korea, Republic of
🇰🇷Ajou university hospital, Suwon, Gyeonggi, Korea, Republic of
🇰🇷Dong-A University Hospital, Busan, Korea, Republic of
Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)
- Conditions
- COVID-19 (Healthy Volunteers)
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- SK Bioscience Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT04760743
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Bundang, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
- Prev
- 1
- 2
- Next